Pantera Life
Mol, BE · 2 known investors
PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.
Founders & leadership
Sv
Sven van den bergheCEO
CM
Christophe MaliceCBO
SB
Samy BertrandCTO
YS
Yves SterckxDirector of Finance & Administration
PV
Philippe VanwolleghemDirector Quality, Regulatory Affairs & HSE